Literature DB >> 16771617

Treatment options for severe sepsis and septic shock.

Vinay K Sharma1, R Phillip Dellinger.   

Abstract

Despite significant advances in the understanding of the pathophysiology of sepsis, severe sepsis and septic shock continue to be associated with high morbidity and mortality. Eradication of infection, with appropriate antibiotics and source control, remains the cornerstone of sepsis management, but does not ensure survival. Aggressive supportive care, such as fluid resuscitation, vasoactive agents or mechanical ventilation, is often required. With the exception of drotrecogin alfa, attempts to modulate the inflammatory response in sepsis have generally been unsuccessful. Early goal-directed therapy targeting adequate central venous oxygen saturation appears to improve outcome. Recently, there has been renewed interest in the use of corticosteroids, not as anti-inflammatory agents, but as replacement therapy. There is also some evidence to suggest that tight glucose control may improve outcome in these patients.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16771617     DOI: 10.1586/14787210.4.3.395

Source DB:  PubMed          Journal:  Expert Rev Anti Infect Ther        ISSN: 1478-7210            Impact factor:   5.091


  7 in total

1.  Population pharmacokinetic/pharmacodynamic modelling of the anti-TNF-α polyclonal fragment antibody AZD9773 in patients with severe sepsis.

Authors:  James W T Yates; Shampa Das; Guy Mainwaring; John Kemp
Journal:  J Pharmacokinet Pharmacodyn       Date:  2012-09-23       Impact factor: 2.745

Review 2.  Matrix metalloproteinases as drug targets in infections caused by gram-negative bacteria and in septic shock.

Authors:  Ineke Vanlaere; Claude Libert
Journal:  Clin Microbiol Rev       Date:  2009-04       Impact factor: 26.132

Review 3.  Complement and sepsis-induced heart dysfunction.

Authors:  Fatemeh Fattahi; Peter A Ward
Journal:  Mol Immunol       Date:  2016-12-05       Impact factor: 4.407

4.  Determination of the safety and efficacy of therapeutic neutralization of tumor necrosis factor-α (TNF-α) using AZD9773, an anti-TNF-α immune Fab, in murine CLP sepsis.

Authors:  Peter Newham; Daniel Ross; Peter Ceuppens; Shampa Das; James W T Yates; Catherine Betts; Jaimini Reens; Kevin J Randall; Richard Knight; Jennifer S McKay
Journal:  Inflamm Res       Date:  2013-11-17       Impact factor: 4.575

5.  A placebo-controlled, double-blind, dose-escalation study to assess the safety, tolerability and pharmacokinetics/pharmacodynamics of single and multiple intravenous infusions of AZD9773 in patients with severe sepsis and septic shock.

Authors:  Peter E Morris; Brian Zeno; Andrew C Bernard; Xiangning Huang; Shampa Das; Timi Edeki; Steven G Simonson; Gordon R Bernard
Journal:  Crit Care       Date:  2012-02-17       Impact factor: 9.097

6.  Mediatory roles of leukotriene B4 receptors in LPS-induced endotoxic shock.

Authors:  Sun-Young Kwon; MyungJa Ro; Jae-Hong Kim
Journal:  Sci Rep       Date:  2019-04-11       Impact factor: 4.379

7.  Whey Acidic Protein/Four-Disulfide Core Domain 21 Regulate Sepsis Pathogenesis in a Mouse Model and a Macrophage Cell Line via the Stat3/Toll-Like Receptor 4 (TLR4) Signaling Pathway.

Authors:  Zhixiang Xie; Zhuangbo Guo; Jianfeng Liu
Journal:  Med Sci Monit       Date:  2018-06-14
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.